Jessica Ley
About
Jessica Ley is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Jessica Ley has authored 58 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 35 papers in Otorhinolaryngology and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jessica Ley's work include Head and Neck Cancer Studies (35 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Treatments and Mutations (19 papers). Jessica Ley is often cited by papers focused on Head and Neck Cancer Studies (35 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Treatments and Mutations (19 papers). Jessica Ley collaborates with scholars based in United States, Czechia and Taiwan. Jessica Ley's co-authors include Douglas R. Adkins, Kathryn Trinkaus, Peter Oppelt, Tanya M. Wildes, Hiram A. Gay, Wade L. Thorstad, Brian Nussenbaum, Loren S. Michel, James S. Lewis and Paul Mehan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
In The Last Decade
Jessica Ley
54 papers receiving 602 citations
Peers
Jessica Ley
Andy Karabajakian France
Amy Meister United States
Ming‐Huang Hong China
Annette M. Lim Australia
Grace Kusumawidjaja Singapore
Olga Torres Cuba
Xinxin Shu United States
I. Haas Germany
Normando Iznaga Cuba
Greta Garrido Cuba
Citations per year, relative to Jessica Ley Jessica Ley (= 1×)
peers
Andy Karabajakian
Countries citing papers authored by Jessica Ley
Since
Specialization
Citations
This map shows the geographic impact of Jessica Ley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica Ley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica Ley more than expected).
Fields of papers citing papers by Jessica Ley
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jessica Ley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica Ley. The network helps show where Jessica Ley may publish in the future.
Co-authorship network of co-authors of Jessica Ley
This figure shows the co-authorship network connecting the top 25 collaborators of Jessica Ley. A scholar is included among the top collaborators of Jessica Ley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica Ley. Jessica Ley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Oppelt, Peter, Sidharth V. Puram, Jingxia Liu, Jessica Ley, & Douglas R. Adkins. (2025). Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial. Cancers. 17(3). 437–437.
2.
Puram, Sidharth V., Randal C. Paniello, Patrik Pipkorn, et al.. (2025). Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311. Otolaryngology. 173(2). 410–419.
3.
Oppelt, Peter, Jessica Ley, Jingxia Liu, & Douglas R. Adkins. (2024). Olaparib, a poly (ADP-ribose) polymerase (PARP) Inhibitor, in Combination with Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC): A Single-Arm, Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 118(5). e42–e43.
4.
Adkins, Douglas, Jessica Ley, Jingxia Liu, & Peter Oppelt. (2024). Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial. The Lancet Oncology. 25(7). 888–900.
5.
Lee, David S., Dorina Kallogjeri, Wade L. Thorstad, et al.. (2023). Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma. Otolaryngology. 168(5). 1089–1096.
6.
Oppelt, Peter, Jessica Ley, Randal C. Paniello, et al.. (2023). Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.. Journal of Clinical Oncology. 41(16_suppl). 6015–6015.
7.
Zaretsky, Jesse M., Jessica Ley, Peter Oppelt, et al.. (2023). Phase 2 trial of three schedules of CUE-101 administered before surgery or chemoradiotherapy in HLA-A*0201 positive patients with HPV16+ OPSCC.. Journal of Clinical Oncology. 41(16_suppl). TPS6109–TPS6109.
8.
Adkins, Douglas R., et al.. (2023). Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.. Journal of Clinical Oncology. 41(16_suppl). TPS6108–TPS6108.
9.
Adkins, Douglas R., Assuntina G. Sacco, Jessica Ley, et al.. (2021). Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. Oral Oncology. 115. 105192–105192.
10.
Oppelt, Peter, Jessica Ley, Francis P. Worden, et al.. (2021). Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. Oral Oncology. 114. 105164–105164.
11.
Ley, Jessica, Peter Oppelt, Hiram A. Gay, et al.. (2019). nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma. Medical Oncology. 36(11). 93–93.
12.
Adkins, Douglas R., Jessica Ley, Prakash Neupane, et al.. (2019). Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. The Lancet Oncology. 20(9). 1295–1305.
13.
Hagemann, Ian S., Jessica Ley, Kevin Chen, et al.. (2019). Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer. Medical Oncology. 37(2). 12–12.
14.
Cao, Song, Kristine M. Wylie, Alla Karpova, et al.. (2019). Dynamic host immune response in virus-associated cancers. Communications Biology. 2(1). 109–109.
15.
Adkins, Douglas R., Jessica Ley, Omar Atiq, et al.. (2018). Multicenter Phase 2 Trial of C is/Carboplatin, nAb -Paclitaxel, and C e TUX imab ( CACTUX ) as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1311–1312.
16.
Lewis, James S., Jessica Ley, Tanya M. Wildes, et al.. (2016). Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology. 11(3). 338–345.
17.
Schell, Amy E., Jessica Ley, Ningying Wu, et al.. (2015). Nab‐paclitaxel‐based compared to docetaxel‐based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. Cancer Medicine. 4(4). 481–489.
18.
Touma, Waseem, Jessica Ley, Tanya M. Wildes, et al.. (2014). Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. Oral Oncology. 50(9). 895–900.
19.
Ley, Jessica. (2014). Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma. ecancermedicalscience. 8. 480–480.
20.
Ley, Jessica, Paul Mehan, Tanya M. Wildes, et al.. (2013). Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncology. 85(5). 290–296.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Andy Karabajakian Breakdown of academic impact, for papers by Amy Meister Breakdown of academic impact, for papers by Ming‐Huang Hong Breakdown of academic impact, for papers by Annette M. Lim Breakdown of academic impact, for papers by Grace Kusumawidjaja Breakdown of academic impact, for papers by Olga Torres Breakdown of academic impact, for papers by Xinxin Shu Breakdown of academic impact, for papers by I. Haas Breakdown of academic impact, for papers by Normando Iznaga Breakdown of academic impact, for papers by Greta Garrido